Latest news with #MedianTechnologies
Business Wire
28-05-2025
- Business
- Business Wire
Median Technologies announces the availability of the preparatory documents for the Shareholders' Ordinary and Extraordinary General Meeting on June 17, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: The shareholders of Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, 'Median' or 'The Company') are invited to participate in the Shareholders' Ordinary and Extraordinary General Meeting which will be held on Tuesday, June 17, 2025, at 10:30 am CEST at PDGB, 174 avenue Victor Hugo – 75116 Paris. All useful information relating to this Shareholders' General Meeting is regularly updated on Median Technologies website. Shareholders may exercise their voting rights before the holding of the Shareholders' General Meeting, either by returning their postal voting form, or by giving proxy. The detailed procedures relating to the exercise of the right to vote are specified in the notice of the Shareholders' General Meeting, available here on Median's website The preliminary notice of the Shareholders' General Meeting has been published in the BALO (Bulletin des annonces légales obligatoires) on May 9, 2025, and has not been subject to any modification. The documents referred to in Article R.225-83 of the French Commercial Code are made available to Shareholders as from the date of the convening notice for the Meeting in accordance with applicable regulations: Registered shareholders may, up to and including the fifth day prior to the Meeting, request that the company sends these documents to them free of charge. For shareholders holding bearer shares, the exercise of this right is subject to the provision of a certificate of registration in the accounts of the bearer shares issued by the authorized intermediary. Shareholders may consult these documents at the company's registered office, Les 2 Arcs, 1800 route des Crêtes – 06560 Valbonne, under the conditions provided for by applicable regulations. The documents to be communicated within the context of the Shareholders' General Meeting may be consulted and downloaded on Median Technologies' website under the 'Shareholder Meetings' section here. About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
Yahoo
27-05-2025
- Business
- Yahoo
Median Technologies to Showcase iCRO's Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
Median is a leading provider of imaging services to the world's top oncology pharma companies ASCO abstracts position Median as highly differentiated provider of AI-imaging services for oncology trials Median will host two presentation sessions to introduce its new solution for radiopharmaceutical image processing for oncology research at booth #11046 SOPHIA ANTIPOLIS, France, May 27, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will be participating in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 30 to June 2, McCormick Place, Chicago, IL, USA. Median's team will be hosting interested parties at booth #11046, South Building, Hall A, McCormick Place, from May 31 to June 2 (exhibit dates), from 9:00 am to 5:00 pm CT, where it will share the most recent advances for its central and AI-powered imaging services for oncology clinical trials. Median Technologies' abstracts selected for online publication are available on the ASCO platform: Abstract e24073: Technical Performance of the L3 Skeletal Muscle Index in CT Abstract e13590: Using tumor growth modeling and informed neural networks as early predictive clinical endpoints Median will host two 30-minute presentation sessions on how the Company's new solution for radiopharmaceutical image processing is advancing oncology research. Sessions will take place at booth #11046 on Saturday, May 31 and Sunday, June 1, 11:30 am -12:00 pm CT. The ASCO Annual Meeting is the world's premier oncology conference, organized by the American Society of Clinical Oncology, the largest oncology society in the world. Each year, the ASCO conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO Annual Meeting: About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts MEDIAN TECHNOLOGIES Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - SEITOSEI ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 U.S. media & investors - COHESION BUREAU Chris Maggos+41 79 367 Press – ULYSSE COMMUNICATION Bruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, May 16, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 19,129,120 Number of real voting rights* (excluding treasury shares**) 19,065,961 Theoretical number of voting rights* (including treasury shares**) 19,105,920 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 Press – Ulysse Communication Bruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@
Business Wire
16-05-2025
- Business
- Business Wire
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
Yahoo
16-05-2025
- Business
- Yahoo
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. SOPHIA ANTIPOLIS, France, May 16, 2025--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 19,129,120 Number of real voting rights* (excluding treasury shares**) 19,065,961 Theoretical number of voting rights* (including treasury shares**) 19,105,920 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF's General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit View source version on Contacts Median Technologies Emmanuelle LeyguesVP, Corporate Marketing & Financial Communications+33 6 10 93 58 Investors - ACTIFIN Ghislaine Gasparetto+33 6 21 10 49 Press – Ulysse Communication Bruno Arabian+33 6 87 88 47 26barabian@ Nicolas Entz+33 6 33 67 31 54nentz@
